Lifemd, INC

LifeMD reported record subscriber growth in Q1 2026, achieving 365,000 active users while affirming full-year revenue guidance.

LifeMD, Inc. announced the appointment of Atul Kavthekar as its new Chief Financial Officer, alongside other key leadership promotions.

LifeMD, Inc. announced the closing of a new senior secured revolving credit facility with Citizens Bank, N.A., providing up to $50 million in capital for corporate development and shareholder value initiatives.

LifeMD, Inc. reported a 13% year-over-year revenue increase to $60.2 million in Q3 2025, alongside a 20% rise in adjusted EBITDA and the complete payoff of outstanding debt.

LifeMD, Inc. has rescheduled its third quarter 2025 earnings release and conference call to November 17, 2025, due to identified accounting corrections impacting prior period revenue recognition.

LifeMD, Inc. announced the sale of its majority ownership interest in WorkSimpli Software LLC for an enterprise value of approximately $65 million, sharpening its focus on virtual healthcare and pharmacy.

LifeMD reports Q1 2026 results with $50.2 million in telehealth revenue and highlights ongoing efforts to remediate material weaknesses in internal controls.

LifeMD, Inc. reported a significant reduction in net losses for Q3 and the first nine months of 2025, driven by strong telehealth revenue growth, while announcing the strategic sale of its WorkSimpli subsidiary.

LifeMD, Inc. reported a significant financial turnaround in Q2 2025, achieving positive net income and robust revenue growth driven by its telehealth segment.

LifeMD's Q1 2025 results show a significant revenue increase driven by telehealth growth, with the company reporting net income and improved operational efficiencies.

LifeMD, Inc. has extended its office lease and reported a 38% increase in revenue for the third quarter of 2024, driven by telehealth services.

LifeMD, Inc. saw a significant 41% increase in revenue in the second quarter of 2024, driven by a 67% surge in telehealth revenue, while also addressing internal control weaknesses.

LifeMD's 2024 10-K filing highlights a 39% increase in revenue, driven by telehealth services, and details strategic initiatives including the launch of a wholly-owned pharmacy and expansion into commercial insurance.

LifeMD, Inc. experienced a 28% increase in total revenue in 2023, fueled by growth in both its telehealth and WorkSimpli segments.

LifeMD Chief Technology Officer Umesh Sripad was granted 75,000 restricted stock units as part of a long-term incentive plan.

LifeMD CFO Atul Kavthekar was granted 337,500 restricted stock units as part of an equity compensation package.

LifeMD's Chief Marketing Officer, Christopher A. Pisano, was granted 200,000 restricted stock units with a multi-year vesting schedule.

LifeMD's Chief Marketing Officer, Jessica Friedeman, reported the sale of 15,000 shares of common stock at a weighted average price of $3.6105.

LifeMD, Inc. Director John R. Strawn Jr. is set to acquire 22,365 shares of common stock at no cost on October 6, 2025, with vesting scheduled for June 1, 2026.

LifeMD, Inc. Director Joan LaRovere was granted 22,365 restricted shares of common stock, vesting on June 1, 2026, increasing her total beneficial ownership to 107,050 shares.

LifeMD, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

LifeMD, Inc. has released its proxy statement detailing the agenda for its upcoming virtual annual meeting of stockholders on June 13, 2025, including the election of directors and ratification of the company's independent accounting firm.

LifeMD is asking stockholders to approve an amendment to its 2020 Equity and Incentive Plan, increasing the share pool by 3,000,000 and raising the non-employee director compensation limit to $500,000.

LifeMD, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

LifeMD is asking stockholders to approve an amendment to its 2020 Equity and Incentive Plan to increase the number of shares available for issuance by 3,000,000.

Federated Hermes, Inc. and related entities have reported beneficial ownership of 5.68% of LifeMD, Inc. common stock as of June 30, 2026.